James M. Frates, Director at Sage Therapeutics, Inc. (SAGE), sold 7,000 shares at $154.00 ($1.1M) on 2018-05-08, disclosed to the SEC on 2018-05-08.
Open-market sale of $1.1M SAGE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| AMLX | SELL | 2026-02-04 | $52K | — | Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |